瘦素及其受体基因多态性与高血压相关性的Meta分析

摘要/Abstract

摘要：

目的:系统评价瘦素（LEP）及其受体（LEPR）基因多态性与高血压的相关性。方法: 通过中国知网（CNKI）、维普、万方数据库、Pubmed、EMBASE等中外数据库，查全瘦素及其受体基因与高血压相关文献，按照Newcastle-Ottawa Scale质量评价标准对文献进行质量评价，使用STATA11.0对数据进行分析。结果:纳入21篇文献，共7 832例研究对象，病例组4 736例，对照组3 096例。Meta分析结果，LEP基因II/I在隐性和加性模型下与高血压相关（隐性模型：OR=2.16，95%CI=1.08-4.31，P=0.029，加性模型：OR=2.27，95%CI=1.08-4.79，P=0.031）；LEPR基因Gln223Arg在显性和等位基因模型下与高血压相关（显性模型：OR=1.55，95%CI=1.14-2.11，P=0.005,等位基因：OR=1.36，95%CI=1.09-1.71，P=0.007）；Lys109Arg与高血压无显著相关（显性模型OR=0.87，95%CI=0.67-1.14，P=0.307，隐性模型：OR=0.91，95%CI=0.70-1.20，P=0.099，加性模型：OR=0.92，95%CI=0.70-1.21，P=0.071，等位基因模型：OR=1.04，95%CI=0.80-1.35，P=0.830)。结论:LEP基因II/I与高血压相关，提示携带I/I基因型是高血压发病危险因素。LEPR基因Gln223Arg与高血压相关，且携带AA+AG基因型、A等位基因是高血压发病的危险因素；Lys109Arg与高血压无显著相关。

关键词: 高血压, 瘦素, 瘦素受体, 基因多态性, Meta分析

Abstract:

AIM: To evaluate the association between leptin gene and leptin receptor gene polymorphisms with hypertension. METHODS: CNKI, Wanfang database, Chongqing VIP network, Pubmed database and EMBASE database were researched. The data on the relationship between leptin/its receptor gene and hypertension were extracted and evaluated by software STATA11.0. RESULTS: Twenty-one studies involving 4 736 patients and 3 096 healthy people were included. The meta-analysis showed the II/I polymorphism of LEP gene was associated with hypertension in recessive genetic model and additive genetic model (recessive genetic model: OR=2.16, 95%CI=1.08-4.31, P=0.029, additive genetic model: OR=2.27, 95%CI=1.08-4.79, P=0.031); the Gln223Arg polymorphism of LEPR gene was associated with hypertension in dominant model and allelic model (dominant model: OR=1.55, 95%CI=1.14-2.11, P=0.005; allelic model: OR=1.36，95%CI=1.09-1.71, P=0.007). No statistically significant correlation was found between the Lys109Arg polymorphism of LEPR gene and hypertension (dominant model: OR=0.87, 95%CI=0.67-1.14, P=0.307, recessive genetic model: OR=0.91, 95%CI=0.70-1.20, P=0.099, additive genetic model: OR=0.92, 95%CI=0.70-1.21, P=0.071, allelic model: OR=1.04, 95%CI=0.80-1.35, P=0.830). CONCLUSION: There is no significant correlation between Lys109Arg polymorphism of LEPR gene and hypertension, but the II/I polymorphism of LEP gene and Gln223Arg polymorphism of LEPR gene are associated with hypertension.

Key words: hypertension, leptin, leptin receptor, gene polymorphism, Meta-analysis

中图分类号:

R544.1

张晓宇，方正美，姚应水. 瘦素及其受体基因多态性与高血压相关性的Meta分析[J]. 中国临床药理学与治疗学, 2017, 22(8): 910-916.

ZHANG Xiaoyu, FANG Zhengmei, YAO Yingshui. Association of leptin and leptin receptor gene polymorphisms with hypertension: a Meta-analysis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 910-916.

参考文献

［1］Della-Morte D, Guadagni F, Palmirotta R, et al. Genetics of ischemic stroke, stroke-related risk factors, stroke precursors and treatments［J］. Pharmacogenomics, 2012, 13(5): 595-613.
［2］纪智，郭文，朱华超，等. 以基因芯片探究针刺泻法对应激性高血压前期大鼠肾脏基因表达的影响［J］. 长春中医药大学学报，2016, 32(3): 458-461.
［3］Harlan SM, Rahmouni K. Neuroanatomical determinants of the sympathetic nerve responses evoked by leptin ［J］. Clin Auton Res, 2013, 23(1): 1-7.
［4］Mark AL. Selective leptin resistance revisited［J］. Am J Physiol Regul Integr Comp Physiol, 2013, 305(6): R566-581.
［5］Agata J, Masuda A, Takada M, et al. High plasma immunoreactive leptin level in essential hypertension［J］. Am J Hypertens, 1997, 10(10): 1171-1174.
［6］谢平，邓振霞，许岚. Ⅱ型糖尿病患者瘦素受体基因变异与肥胖及高血压的相关性研究［J］. 中国优生与遗传杂志，2002, 10(6): 34-35.
［7］吴红赤，王明奡. 瘦素受体基因多态性与高血压肾损害及肾实质性高血压［J］. 中华医学杂志，2004, 84(11): 36-38.
［8］王楠，成蓓，马丽雅. 原发性高血压患者左心室功能及临床变量与瘦素受体基因变异的关系［J］. 临床心血管病杂志，2007, 23(4): 259-261.
［9］施有为，张艳斌，罗昭峰，等. 高血压胰岛素抵抗与瘦素受体基因变异的研究［J］. 中华内科杂志，2007, 46(3): 238-239.
［10］潘若望，石南松，张恩勇，等. 瘦素受体基因Gln223Arg多态性与温州地区高血压合并肥胖的相关性研究［J］. 解放军医学杂志，2008, 33(10): 1192-1194.
［11］赵林双，向光大，唐瑛，等. 武汉地区高血压合并肥胖与瘦素受体基因GIN223Arg变异的关系［J］. 中国慢性病预防与控制，2007, 15(2): 91-94.
［12］顾萍，蒋卫民，王坚，等. 瘦素受体基因多态性与高血压病及其临床代谢特征的相关性研究［J］. 临床内科杂志，2009, 26(11): 762-765.
［13］王楠，成蓓，马丽雅. 高血压患者左心室功能及肾脏血流动力学与瘦素受体基因外显子4Lys109Arg变异的关系［J］. 中国医师进修杂志，2010, 33(1): 13-15.
［14］蔡泽园，赵福梅，刘婷，等. 瘦素受体基因多态性与原发性高血压及血脂的关系［J］. 天津医药，2011, 39(3): 196-198.
［15］包博侃，应俊，张洪勤，等. 瘦素受体基因Lys109Arg多态性与温州地区高血压合并肥胖的相关性研究［J］. 中国优生与遗传杂志，2010, 40(12): 20-22.
［16］王先梅，李春城，杨丽霞. 瘦素受体基因多态性与云南地区高血压合并肥胖的相关性［J］. 中国动脉硬化杂志，2012, 20(11): 1007-1012.
［17］高丽，管立学，李海波，等. 瘦素受体基因3057位G→A变异与妊娠高血压综合征的关系［J］. 中国优生与遗传杂志，2009,17 (10): 23-24.
［18］Liu Y, Lou YQ, Liu K, et al. Role of leptin receptor gene polymorphisms in susceptibility to the development of essential hypertension: a case-control association study in a Northern Han Chinese population［J］. J Hum Hypertens, 2014, 28(9): 551-556.
［19］Gu P, Jiang W, Chen M, et al. Association of leptin receptor gene polymorphisms and essential hypertension in a Chinese population［J］. J Endocrinol Invest, 2012, 35(9): 859-865.
［20］Das B, Pawar N, Saini D, et al. Genetic association study of selected candidate genes (ApoB, LPL, Leptin) and telomere length in obese and hypertensive individuals［J］. BMC Med Genet, 2009, 10(1): 99.
［21］Shintani M, Ikegami H, Fujisawa T, et al. Leptin gene polymorphism is associated with hypertension independent of obesity ［J］. J Clin Endocrinol Metab, 2002, 87(6): 2909-2912.
［22］Maestrini S, Mencarelli M, Verti B, et al. Lack of association between the tetranucleotide repeat polymorphism in the 3'-flanking region of the leptin gene and hypertension in severely obese patients［J］. J Endocrinol Invest, 2006, 29(9): 776-780.
［23］Akhter Q, Masood A, Ashraf R, et al. Polymorphisms in the 3'UTR of the human leptin gene and their role in hypertension［J］. Mol Med Rep, 2012, 5(4): 1058-1062.
［24］Nagalingam S, Uppuluri MV, Gunda P, et al. Evaluation of leptin and leptin receptor gene 3' UTR polymorphisms in essential hypertension［J］. Clin Exp Hypertens, 2014, 36(6): 419-425.
［25］Wiedemann A, Vocke F, Fitzgerald JS, ea al. Leptin gene (TTTC)(n) microsatellite polymorphism as well as leptin receptor R223Q and PPARgamma2 P12A substitutions are not associated with hypertensive disorders in pregnancy［J］. Am J Reprod Immunol, 2010, 63(4): 310-317.
［26］Tennekoon KH, Indika WL, Sugathadasa R, et al. LEPR c.668A>G polymorphism in a cohort of Sri Lankan women with pre-eclampsia / pregnancy induced hypertension: a case control study ［J］. BMC Res Notes, 2012, 5(1): 308.
［27］Winters B, Mo Z, Brooks-Asplund E, et al. Reduction of obesity, as induced by leptin, reverses endothelial dysfunction in obese (Lep(ob)) mice［J］. J Appl Physiol (1985), 2000, 89(6): 2382-2390.
［28］Schutte R, Huisman HW, Schutte AE, et al. Leptin is independently associated with systolic blood pressure, pulse pressure and arterial compliance in hypertensive African women with increased adiposity: the POWIRS study ［J］. J Hum Hypertens, 2005, 19(7): 535-541.
［29］Pena Gd, Guimares AL, Veloso RR, et al. Leptin receptor gene Gln223Arg Polymorphism is not associated with hypertension: a preliminary population-based cross-sectional study［J］. Cardiol Res Pract, 2014, 2014(3): 879037.

[1]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[2]	朱丽, 魏兵, 廖世峨, 张超, 郑晓宇, 刘亚军. 药物代谢酶细胞色素P450单核苷酸多态性影响哮喘儿童吸入皮质醇激素疗效研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 536-543.
[3]	张志英, 靳秀红, 张小宁, 张向峰, 罗青林, 张松林. TBX21和ADCY9多态性在儿童哮喘发生发展中的临床研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 407-412.
[4]	宁思思, 赵玉红, 颜蕾, 唐敏娜, 张凝之, 张泳巧, 崔兆强. 高血压合并慢性肾脏病患者的降压目标之争议[J]. 中国临床药理学与治疗学, 2023, 28(4): 463-467.
[5]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[6]	王爽, 刘嘉, 张月丽. POR*28基因多态性与中国肾移植患者他克莫司稳定剂量的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(9): 991-997.
[7]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[8]	陈文刚, 殷勤, 张巍巍, 周露露, 寇婉青, 袁小龙. 皖南地区高血压患者MTHFR基因多态性分布及与血Hcy相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 768-774.
[9]	武元竹, 刘俊, 杨魁, 彭静, 栾家杰, 韦俊, 张大发, 宋帅, 袁小龙, 王中方, 张年宝, 解丹, 姜鹏, 范洁. 安徽地区汉族人群CYP2C9*3和VKORC1-1639G>A基因多态性分布及对华法林稳定剂量的影响[J]. 中国临床药理学与治疗学, 2022, 27(6): 652-659.
[10]	张凝之, 赵玉红, 唐敏娜, 张泳巧, 宁思思, 崔兆强. 时辰药理学在高血压治疗中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 418-422.
[11]	崔素梅, 崔兆强. β受体阻滞剂与高血压治疗[J]. 中国临床药理学与治疗学, 2022, 27(4): 423-427.
[12]	李远方, 崔兆强. 高血压合并高尿酸血症的应对之策[J]. 中国临床药理学与治疗学, 2022, 27(4): 428-432.
[13]	徐建飞, 林利. 高血压药物治疗与非药物治疗研究进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 433-441.
[14]	蒯铮, 张潇伊, 邹云增. 血管紧张素受体脑啡肽酶抑制剂在老年高血压中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 442-445.
[15]	刘桂剑, 程宽, 朱文青, 葛均波. 高血压的药物治疗进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 446-449.